• Gastrointestinal System Agents, Pancrelipase
    Dosage form: Capsule
    Strength: 8,000 / 30,000 / 30,000 units
    Indications/Special comments: Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole. Benign gastric ulcer. Duodenal ulcer. Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Prophylaxis of NSAID-associated duodenal ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Gastro-oesophageal reflux disease. Zollinger–Ellison syndrome (and other hypersecretory conditions.
    Dosage Administration: Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole - Oral: Adult: 40mg twice daily. Benign gastric ulcer: Oral: Adult: 40mg daily for 8 weeks; increased if necessary up to 80mg daily, dose increased in severe cases. Gastric ulcer: By intravenous injection, or by intravenous infusion: Adult: 40mg daily until oral administration can be resumed, injection to be given over at least 2 minutes. Duodenal ulcer: Oral: Adult:40mg daily for 4 weeks; increased if necessary up to 80mg daily, dose increased in severe cases. By intravenous injection or by intravenous infusion: Adult: 40mg daily until oral administration can be resumed, injection to be given over at least 2 minutes. Prophylaxis of NSAID-associated duodenal ulcer in patients with an increased risk of gastroduodenal complications that require continued NSAID treatment. Oral: Adult: 20mg daily. Gastro-oesophageal reflux disease. Oral: Adult: 20 – 80mg daily for 4 weeks, continued for further 4 weeks if not fully healed, dose to be taken in the morning; maintenance 20mg daily and increased to 40mg daily, increased only if symptoms return. By intravenous injection, or by intravenous infusion: 40mg daily until oral administration can be resumed, injection to be given over at least 2 minutes. Zollinger–Ellison Syndrome (and other hypersecretory conditions). Oral: Adult: Initially, 80mg daily (max. per dose 80mg), adjusted according to response. Elderly: 40mg daily. By intravenous injection, or by intravenous infusion. Oral: initially 80mg, alternatively 160mg in 2 divided doses, if rapid acid control required, then 80mg once daily (max. per dose 80mg), adjusted according to response. Special note: For intravenous infusion pantoprazole, give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute 40mg with 10 mL sodium chloride 0.9% and dilute with 100 mL of infusion fluid; give 40mg over 15 minutes.
    View full drug info
  • Drugs for Correcting Water Electrolyte and Acidbase Disturbances, Potassium Chloride
    Dosage form: Solution
    Strength: 0.1
    Indications/Special comments: Treatment of potassium depletion or hypokalaemia, with or without metabolic alkalosis, in chronic digitalis intoxication, and in patients with hypokalaemia familiar periodic paralysis;
    Dosage Administration: Adult Dosing: Treatment of hypokalemia: Daily dose range from 40 to 100 mEq. Give in 2 to 5 divided doses: limit doses to 40 mEq per dose. The total daily dose should not exceed 200 mEq in a 24 hour period. Maintenance or Prophylaxis: Typical dose is 20 mEq per day. Individualize dose based upon serum potassium levels. Note: Dilute the potassium chloride solution with at least 4 ounces of cold water. Take with meals or immediately after eating
    View full drug info
  • Drugs for Correcting Water Electrolyte and Acidbase Disturbances, Potassium Chloride
    Dosage form: IVPB (premixed)
    Strength: 10mEQ/100ml, 20mEQ/100ml
    Indications/Special comments: Treatment of potassium depletion or hypokalaemia, with or without metabolic alkalosis, in chronic digitalis intoxication, and in patients with hypokalaemia familiar periodic paralysis;
    Dosage Administration: Adult: Antihypokalemic or electrolyte replenisher: IV infusion: the dose and rate of infusion to be determined by the individual requirements of each patient, up to 400mEq of potassium a day (usually not more than 3mEq per kg of body weight). The response of the patient, as determined by the measurement of serum potassium concentration and the electrocardiogram following the initial 40 to 60mEq infusion, should indicate the subsequent infusion rate required. Child: Antihypokalemic or Electrolyte replenisher: IV infusion: up to 3mEq of potassium per kg of body weight or 40mEq per square meter of body surface area a day. Volume of administered fluids must be adjusted to body size.
    View full drug info
  • Drugs for Correcting Water Electrolyte and Acidbase Disturbances, Potassium Chloride
    Dosage form: Injection
    Strength: 2 mEQ/ml in 10ml
    Indications/Special comments: Treatment of potassium depletion or hypokalaemia, with or without metabolic alkalosis, in chronic digitalis intoxication, and in patients with hypokalaemia familiar periodic paralysis;
    Dosage Administration: Note: - Injectable potassium chloride products, in strengths of 1.5mEq and 2mEq per ml must be diluted prior to IV administration. Direct patient injection of potassium concentrate may be instantaneously fatal. However, injectable potassium chloride products in strengths of 0.1 and 0.4mEq per ml are intended for use with a calibrated infusion device and do not require dilution.
    View full drug info
  • Drugs for Correcting Water Electrolyte and Acidbase Disturbances, Potassium Acetate
    Dosage form: Injection
    Strength: 40mEQ/mL
    Indications/Special comments: Potassium Acetate Injection, USP, is indicated in the treatment of potassium deficiency states when oral replacement therapy is not feasible. The solution is intended as an alternative to Potassium Chloride to provide Potassium (K+) for addition to large volume infusion fluids for intravenous use
    Dosage Administration: Children: Treatment of hypokalemia: IV: 2 – 5mEQ/ kg/day; IV intermittent infusion must be diluted before administration 0.5 - 1mEQ/kg/dose to infuse at 0.3 -0.5mEQ/kg/hour, Adults: Treatment for hypokalemia: IV: 40 – 100 mEQ/dayI; IV intermittent infusion must be diluted prior to administration: 5 – 10mEQ per dose max 40mEQ/dose to infuse over 2 - 3 hours. Special note: Continuous cardiac moniter recommended for rates > 0.5mEQ/kg/hour potassium dosage/rate of infusion guidelines: serum potassium > 2.5mEQ/l: maximum infusion rate 10mEQ/hr max concentration: 40mEQ/L maximum 24 hour dose 200mEQ. Serum potassium <2.5mEQ/L maximum infusion rate 80mEQ/L maximum 24 hour dose 400 mEQ.
    View full drug info
  • Drugs for Correcting Water Electrolyte and Acidbase Disturbances, Peptamen Suspension
    Dosage form: Suspension
    Strength: 1cal/g
    Indications/Special comments: Impaired GI function, which may result from the following conditions: malabsorption, pancreatitis, short bowel syndrome, chronic diarrhoea, Crohn’s disease/IBD, cystic fibrosis, delayed gastric emptying, cerebral palsy, malnutrition, malabsorption related to cancer treatment, celiac disease with malabsorption, early enteral feeding, transition from or dual feeding with TPN.
    Dosage Administration: Suitable for these diets: lactose intolerance, gluten-free, low-residue.
    View full drug info
  • Corticosteroidal Preparations, Prednisone
    Dosage form: Tablet
    Strength: 5mg, 20mg
    Indications/Special comments: Treatment of a variety of diseases including: endocrine disorders, rheumatic disorders (adjunct), collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, haematologic disorders, neoplastic diseases, oedematous states, gastrointestinal diseasesMiscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.
    Dosage Administration: Adult: 10 – 20mg daily, adjusted according to response, dose to be take at bedtime. Gastric irritation may be reduced if taken before, during, or immediately after meals or with food or milk. Please see product leaflet.
    View full drug info
  • Corticosteroidal Preparations, Prednisone
    Dosage form: Solution
    Strength: 5mg/ml
    Indications/Special comments: Treatment of a variety of diseases including: endocrine disorders, rheumatic disorders (adjunct), collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, respiratory diseases, haematologic disorders, neoplastic diseases, oedematous states, gastrointestinal diseases.Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement.
    Dosage Administration: Adult: 10 – 20mg daily, adjusted according to response, dose to be take at bedtime. Gastric irritation may be reduced if taken before, during, or immediately after meals or with food or milk. Please see product leaflet.
    View full drug info
  • Corticosteroidal Preparations, Prednisolone
    Dosage form: Tablet
    Strength: 1mg, 5mg, 10mg
    Indications/Special comments: Suppression of inflammatory and allergic disorders; inflammatory bowel disease, asthma, and rheumatic disease, for the treatment of adrenocortical insufficiency and as immune suppression
    Dosage Administration: Suppression of inflammatory and allergic disorders: Oral: Adultand Childinitially up to 10 - 20mg daily (severe disease, up to 60mg daily), preferably taken in the morning after breakfast: dose can often be reduced within a few days, but may need to be continued for several weeks or months: maintenance, 2.5 - 15mg daily or higher; cushingoid features are increasingly likely with doses above 7.5mg daily.
    View full drug info
  • Corticosteroidal Preparations, Prednisolone
    Dosage form: Syrup
    Strength: 5mg/5ml, 15mg/5ml
    Indications/Special comments: Suppression of inflammatory and allergic disorders; inflammatory bowel disease, asthma, and rheumatic disease, for the treatment of adrenocortical insufficiency and as immune suppression
    Dosage Administration: Child: fractions of adult dose may be used (for example, at 1 year 25% of adult dose, at 7 years 50%, and at 12 years 75%) but clinical factors must be given due weight.
    View full drug info